Cargando…
The Relationship between the Gut Microbiome and Metformin as a Key for Treating Type 2 Diabetes Mellitus
Metformin is the first-line pharmacotherapy for treating type 2 diabetes mellitus (T2DM); however, its mechanism of modulating glucose metabolism is elusive. Recent advances have identified the gut as a potential target of metformin. As patients with metabolic disorders exhibit dysbiosis, the gut mi...
Autores principales: | Lee, Chae Bin, Chae, Soon Uk, Jo, Seong Jun, Jerng, Ui Min, Bae, Soo Kyung |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8037857/ https://www.ncbi.nlm.nih.gov/pubmed/33808194 http://dx.doi.org/10.3390/ijms22073566 |
Ejemplares similares
-
Clinical Pharmacokinetics of Approved RNA Therapeutics
por: Jo, Seong Jun, et al.
Publicado: (2023) -
Analytical Method Development of Benzisothiazolinone, a Biocide, Using LC–MS/MS and a Pharmacokinetic Application in Rat Biological Matrices
por: Jo, Seong Jun, et al.
Publicado: (2023) -
The Comprehensive “Omics” Approach from Metabolomics to Advanced Omics for Development of Immune Checkpoint Inhibitors: Potential Strategies for Next Generation of Cancer Immunotherapy
por: Yoon, Sang Jun, et al.
Publicado: (2021) -
Benzisothiazolinone: Pharmacokinetics, Tissue Distribution, and Mass Balance Studies in Rats
por: Jo, Seong Jun, et al.
Publicado: (2023) -
Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?
por: Dzięgielewska-Gęsiak, Sylwia, et al.
Publicado: (2022)